Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion

Brain Research

Volumn 866, Issue 1-2, 2000, Pages 55-64

  Tsuboi, Kyoko ^a,b   Kimber, Teresa A ^a   Shults, Clifford W ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

6 Hydroxydopamine; Calretinin; Striatum; Substantia nigra pars compacta; Tyrosine hydroxylase

Indexed keywords

CALBINDIN; CALRETININ; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CELL LOSS; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; AXONS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DOPAMINE; DRUG RESISTANCE; FEMALE; NEOSTRIATUM; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0034595729     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02219-8     Document Type: Article

References (44)

1. A. Alfahel-Kakunda, W.F. Silverman, Calcium-binding proteins in the substantia nigra and ventral tegmental area during development: correlation with dopaminergic compartmentalization, Dev. Brain Res. 103 (1997) 9-20.
2. M. Bubser, J.L. Scruggs, C.D. Young, A.Y. Deutch, Characterization of the innervation of the rat nucleus accumbens by calretinin-containing neurons of the thalamic paraventricular nucleus, Soc. Neurosci. Abstr. 25 (1999) 1158.
3. K.G. Baimbridge, M.R. Celio, J.H. Rogers, Calcium-binding proteins in the nervous system, Trends Neurosci. 15 (1992) 303-308.
4. M.F. Beal, Aging, energy, and oxidative stress in neurodegenerative diseases, Ann. Neurol. 38 (1995) 357-366.
5. M.F. Beal, Mitochondria, free radicals, and neurodegeneration, Curr. Opin. Neurobiol. 6 (1996) 661-666.
6. 28k, Cell Calcium 11 (1990) 599-602.
7. 28K immunohisto-chemistry, Brain 122 (1999) 1421-1436.
8. P. Damier, E.C. Hirsch, Y Agid, A.M. Graybiel, The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease, Brain 122 (1999) 1437-1448.
9. C.R. Gerfen, The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat, J. Comp. Neurol. 236 (1985) 454-476.
10. C.R. Gerfen, K.G. Baimbridge, J.J. Miller, The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey, Proc. Natl. Acad. Sci. USA 82 (1985) 8780-8784.
11. C.R. Gerfen, K.G. Baimbridge, J. Thibault, The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems, J. Neurosci. 7 (1987) 3935-3944.
12. C.R. Gerfen, The neostriatal mosaic: multiple levels of compartmental organization, Trends Neurosci. 15 (1992) 133-139.
13. 28k-containing cells, Ann. NY Acad. Sci. 648 (1992) 42-62.
14. D.C. German, K.F. Manaye, Midbrain dopaminergic neurons (nuclei A8, A9, and A10): Three-dimensional reconstruction in the rat, J. Comp. Neurol. 331 (1993) 297-309.
15. W.R.G. Gibb, Neuropathology of Parkinson's disease and related syndromes, Neurol. Clin. 10 (1992) 361-376.
16. A.M. Graybiel, Correspondence between the dopamine islands and striosomes of the mammalian striatum, Neuroscience 13 (1984) 1157-1187.
17. R.H. Haas, F. Nasirian, K. Nakono, D. Ward, M. Pay, R. Hill, C.W. Shults, Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease, Ann. Neurol. 37 (1995) 714-722.
18. N. Hiroi, Compartmental organization of calretinin in the rat striatum, Neurosci. Lett. 197 (1995) 223-226.
19. E.C. Hirsch, Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?, Ann. Neurol. 32 (1992) S88-S93.
20. 28k-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson's disease, Neurodegeneration 1 (1992) 83-93.
21. 28k and parvalbumin neurons and fibers in the rat basal ganglia, Brain Res. Bull. 47 (1998) 107-116.
22. K.R. Isaacs, D.M. Jacobowitz, Mapping of the colocalization of calretinin and tyrosine hydroxylase in the rat substantia nigra and ventral tegmental area, Exp. Brain Res. 99 (1994) 34-42.
23. K.R. Isaacs, G. de Erausquin, K.I. Strauss, D.M. Jacobowitz, I. Hanbauer, Differential effects of excitatory amino acids on mesencephalic neurons expressing either calretinin or tyrosine hydroxylase in primary cultures, Mol. Brain Res. 36 (1996) 114-126.
24. K.R. Isaacs, M.E. Wolpoe, D.M. Jacobowitz, Calretinin-immunoreactive dopaminergic neurons from embryonic rat mesencephalon are resistant to levodopa-induced neurotoxicity, Exp. Neurol. 146 (1997) 25-32.
25. P. Jenner, D.T. Dexter, J. Sian, A.H.V. Schapira, C.D. Marsden, Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease, Ann. Neurol. 32 (1992) S82-S87.
26. 2+-overload or trophic factor deprivation, Biochim. Biophys. Acta 1313 (1996) 194-200.
27. 28k exhibit reduced vulnerability to MPTP-induced neurodegeneration, Neurodegeneration 5 (1996) 313-318.
28. 28k expression in the striatal matrix, J. Comp. Neurol. 320 (1992) 304-322.
29. 28k buffers intracellular calcium and promotes resistance to degeneration in PC12 cells, Mol. Brain Res. 54 (1998) 56-63.
30. A. Mouatt-Prigent, Y. Agid, E.C. Hirsch, Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?, Brain Res. 668 (1994) 62-70.
31. D. Offen, P.M. Beart, N.S. Cheung, C.J. Pascoe, A. Hochman, S. Gorodin, E. Melamed, R. Bernard, O. Bernerd, Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxy-dopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity, Proc. Natl. Acad. Sci. USA 95 (1998) 5789-5794.
32. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego, 1986.
33. A. Persechini, N.D. Moncrief, R.H. Kretsinger, The EF-hand family of calcium modulated proteins, Trends Neurosci. 12 (1989) 462-467.
34. J.H. Rogers, Calretinin: a gene for a novel calcium binding protein expressed principally in neurons, J. Cell Biol. 105 (1987) 1343-1353.
35. 28k with tyrosine hydroxylase, Brain Res. 587 (1992) 203-210.
36. 28k in rat brain: patterns of partial co-localization, Neuroscience 51 (1992) 843-865.
37. H. Sauer, W.H. Oertel, Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat, Neuroscience 59 (1994) 401-415.
38. H. Sauer, C. Rosenblad, A. Björklund, Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion, Proc. Natl. Acad. Sci. USA 92 (1995) 8935-8939.
39. U. Seifert, W. Härtig, J. Grosche, G. Brückner, A. Riedel, K. Brauer, Axonal expression sites of tyrosine hydroxylase, calretinin- and calbindin-immunoreactivity in striato-pallidal and septal nuclei of the rat brain: a double-immunolabelling study, Brain Res. 795 (1998) 227-246.
40. M.G. Spillantini, M.L. Schmidt, V.M.-Y. Lee, J.Q. Trojanowski, R. Jakes, M. Goedert, α-Synuclein in Lewy bodies, Nature 388 (1997) 839-840.
41. C. Winkler, H. Sauer, C.S. Lee, A. Björklund, Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease, J. Neurosci. 16 (1996) 7206-7215.
42. L. Winsky, H. Nakata, B.M. Martin, D.M. Jacobowitz, Isolation, partial amino acid sequence, and immunohistochemical localization of a brain-specific calcium-binding protein, Proc. Natl. Acad. Sci. USA 86 (1989) 10139-10143.
43. D.S. Zahm, Compartments in rat dorsal and ventral striatum revealed following injection of 6-hydroxydopamine into the ventral mesencephalon, Brain Res. 552 (1991) 164-169.
44. M.J. Zigmond, E.M. Stricker, Animal models of parkinsonism using selective neurotoxins: clinical and basic implications, Int. Rev. Neurobiol. 31 (1989) 1-79.